Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome

Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome

Interleukin-1 (IL-1)-blocking therapies are effective in reducing disease severity and inflammation in Schnitzler syndrome. Here, we present a patient with Schnitzler syndrome treated successfully using canakinumab for over 10 years. Complete clinical response was associated with a decrease in derma...

Full description

Bibliographic Details
Main Authors: Simon Bossart, S. Morteza Seyed Jafari, Kristine Heidemeyer, Kexiang Yan, Laurence Feldmeyer, Luca Borradori, Nikhil Yawalkar
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Medicine
Subjects:
Canakinumab
Schnitzler syndrome
neutrophilic inflammation
immunohistochemical
autoinflammatory disorders
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1050230/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1050230/full

Similar Items